Asco 2023 Characterizing Progression To Subsequent Lines Of Therapy In 4538 background: treatment patterns and number of lines of therapy for patients with mrcc are not well characterized in the era of immunoncology based combinations. we aimed to quantify the attrition rates by line of therapy and to examine predictors of receiving second line (2l) treatment. methods: using the imdc, patients with mrcc who received first line (1l) nivo ipi were included. Asco 2023: characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma after nivolumab plus ipilimumab (nivo ipi): results from the imdc (urotoday ) the 2023 american society of clinical oncology (asco) annual meeting held in chicago, il between june 2 nd and june 6 th was host to a kidney and bladder cancers.
Subsequent Line Treatment Options For Hepatocellular Carcinoma With From june 2 to june 6, 2023, oncologists from around the world convened at the american society of clinical oncology (asco) annual meeting to share the latest research and insights on treating. September 10, 2023. presented here are some brief summaries of novel therapies under study from the 2023 asco breakthrough meeting in yokohama, japan. the subjects range from new observations about a her2 directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand foot syndrome in patients on capecitabine. Oral presentation at: american society of clinical oncology (asco) gastrointestinal cancers symposium; january 19 21, 2023; san francisco, ca. abstract 489. 10. Io io (nivolumab ipilimumab) was the most common previous first line therapy (30.5% among patients subsequently receiving atezolizumab cabozantinib vs 27.1% for patients subsequently receiving cabozantinib). io monotherapy was the most common second line therapy (87.% in the atezolizumab cabozantinib arm vs 92.8% in the cabozantinib arm).
Comments are closed.